Compare CYTK & GBCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | GBCI |
|---|---|---|
| Founded | 1997 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.3B |
| IPO Year | 2004 | 1996 |
| Metric | CYTK | GBCI |
|---|---|---|
| Price | $61.52 | $43.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $88.50 | $53.60 |
| AVG Volume (30 Days) | ★ 1.8M | 947.9K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | ★ 18.45 |
| EPS | N/A | ★ 1.99 |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $8.73 | $31.62 |
| Revenue Next Year | $309.93 | $8.37 |
| P/E Ratio | ★ N/A | $21.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.31 | $36.76 |
| 52 Week High | $70.98 | $53.99 |
| Indicator | CYTK | GBCI |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 35.54 |
| Support Level | $59.13 | $42.78 |
| Resistance Level | $65.72 | $43.90 |
| Average True Range (ATR) | 2.57 | 1.28 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 49.44 | 32.97 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.